# A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older

> **NCT06551181** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 2621 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **BIOLOGICAL:** RSVPreF3 OA investigational vaccine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06551181
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-05
- **Primary completion:** 2025-04-24
- **Final completion:** 2025-09-15
- **Target enrollment:** 2621 (ACTUAL)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06551181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06551181, "A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06551181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*